TradeFlare's AI research teams analysed QURE on 14 market nights between June 24, 2026 and September 8, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 8, 2026 | HOLD | $44.50 | $51.77 / $37.83 | -5.7% | -49.5% | The stock is consolidating, and the technicals are bearish, suggesting a need for further price action confirmation before entering. |
| September 7, 2026 | HOLD | $44.50 | — / — | -5.7% | -49.5% | The stock is not a buy at this time due to conflicting signals and high risk. |
| September 4, 2026 | HOLD | $44.86 | — / — | +1.0% | -48.8% | The current market regime and stock-specific factors do not support a BUY recommendation. |
| September 3, 2026 | HOLD | $46.23 | — / — | -0.8% | -47.7% | The current market and stock-specific factors do not support a BUY recommendation. |
| August 6, 2026 | BUY | $44.24 | — / — | +3.8% | -1.1% | Positive regulatory progress on Huntington's disease therapy. |
| August 4, 2026 | BUY | $44.06 | — / — | +3.0% | +9.6% | Continued positive developments and regulatory progress for AMT-130 in Huntington's disease. |
| August 3, 2026 | BUY | $43.63 | — / — | +4.5% | +10.5% | The stock is currently consolidating and a clear directional bias has not yet emerged. |
| July 29, 2026 | BUY | $36.66 | — / — | +10.4% | +27.1% | Positive clinical trial data for gene therapy candidates. |
| July 28, 2026 | BUY | $38.21 | — / — | +19.1% | +39.2% | Positive FDA feedback and upcoming MHRA submission for AMT-130. |
| July 17, 2026 | HOLD | $39.36 | — / — | -3.2% | +20.8% | Positive news flow driven by regulatory advancements for Huntington's disease therapy. |
| July 16, 2026 | BUY | $41.00 | — / — | +0.2% | +19.6% | The current market regime is neutral, and the stock's internal signals do not warrant a trade. |
| June 26, 2026 | BUY | $49.10 | $62.96 / $40.90 | -12.9% | -19.6% | The post-earnings drift signal suggests a sustained upward move over the coming weeks. |
| June 25, 2026 | BUY | $48.85 | — / — | -14.8% | -20.6% | Positive FDA feedback and strong clinical trial updates for its Huntington's disease therapy. |
| June 24, 2026 | BUY | $49.04 | — / — | -7.5% | -19.3% | The stock is currently consolidating and requires further price action confirmation before a trade can be initiated. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.